---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-148602"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:37:17.357473+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# bluebird bio CFO Christopher Krawtschuk departs June 10; O. James Sterling appointed as CFO

## Summary
- CFO Christopher Krawtschuk to depart June 10, 2024, not due to any disagreement with the company on accounting policies or strategy.
- O. James Sterling, formerly CFO of Renalytix plc, appointed as CFO and principal accounting officer effective June 10, 2024.
- Sterling's compensation: $500k base salary, $100k sign-on bonus, 45% target bonus, and initial equity grant of 300k options, 100k RSUs, and 50k PRSUs (subject to shareholder approval).
- Severance upon termination without cause or for good reason includes one times base salary (or one times base plus target bonus within 12 months of Change in Control) plus COBRA subsidy for 12 months.

## SEC filing metadata
- accession: 0001193125-24-148602
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/d796778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-148602
- JSON: https://secwatch.observer/filing/0001193125-24-148602.json
- Plain text: https://secwatch.observer/filing/0001193125-24-148602.txt

## Key facts
- Executive change
  Christopher Krawtschuk departed as Chief Financial Officer at bluebird bio, Inc..
  - Action: will depart
  - Role: Chief Financial Officer
  source text: Effective June 10, 2024 (the “Separation Date”), Christopher Krawtschuk will depart bluebird bio, Inc. (the “Company”) and cease serving as Chief Financial Officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm
- Executive change
  O. James Sterling was appointed as Chief Financial Officer at bluebird bio, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 28, 2024, the Board of Directors (the “Board”) appointed O. James Sterling as Chief Financial Officer of the Company and designated Mr. Sterling as principal accounting officer, effective as of the date Mr. Sterling commences employment with the Company, which is expected to be June 10, 2024 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.